<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006164.pub2" GROUP_ID="ENDOC" ID="238305021509505186" MERGED_FROM="" MODIFIED="2008-11-04 12:15:42 +0100" MODIFIED_BY="Bernd Richter" REVIEW_NO="CL07" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-11-04 12:04:52 +0100" MODIFIED_BY="Bernd Richter">
<TITLE>Interventions for the prevention of nutritional rickets in term born children</TITLE>
<CONTACT>
<PERSON ID="835127E082E26AA2004333599A94DF8B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Christian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lerch</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate, Cochrane Metabolic &amp; Endocrine Disorders Group</POSITION>
<EMAIL_1>t.c.l@gmx.net</EMAIL_1>
<EMAIL_2>Christian.Lerch@med.uni-duesseldorf.de</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Practice</DEPARTMENT>
<ORGANISATION>Universitaetsklinikum Duesseldorf, Heinrich-Heine University</ORGANISATION>
<ADDRESS_1>PO Box 101007</ADDRESS_1>
<ADDRESS_2/>
<CITY>Duesseldorf</CITY>
<ZIP>40001</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 211 8104575</PHONE_1>
<PHONE_2/>
<FAX_1>+49 211 8118693</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-04 12:04:52 +0100" MODIFIED_BY="Bernd Richter">
<PERSON ID="835127E082E26AA2004333599A94DF8B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Christian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lerch</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate, Cochrane Metabolic &amp; Endocrine Disorders Group</POSITION>
<EMAIL_1>t.c.l@gmx.net</EMAIL_1>
<EMAIL_2>Christian.Lerch@med.uni-duesseldorf.de</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Practice</DEPARTMENT>
<ORGANISATION>Universitaetsklinikum Duesseldorf, Heinrich-Heine University</ORGANISATION>
<ADDRESS_1>PO Box 101007</ADDRESS_1>
<ADDRESS_2/>
<CITY>Duesseldorf</CITY>
<ZIP>40001</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 211 8104575</PHONE_1>
<PHONE_2/>
<FAX_1>+49 211 8118693</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="61F8179782E26AA2011EF9F6030BEE42" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Thomas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Meissner</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer</POSITION>
<EMAIL_1>thomas.meissner@med.uni-duesseldorf.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Pediatrics</DEPARTMENT>
<ORGANISATION>University Children's Hospital</ORGANISATION>
<ADDRESS_1>Moorenstraße 5</ADDRESS_1>
<ADDRESS_2/>
<CITY>Düsseldorf</CITY>
<ZIP>40221</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-10-22 11:49:23 +0200" MODIFIED_BY="Gudrun Paletta">
<UP_TO_DATE>
<DATE DAY="22" MONTH="8" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="8" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="8" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="22" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-22 11:41:29 +0200" MODIFIED_BY="Gudrun Paletta"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Heinrich-Heine University</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-04 12:13:22 +0100" MODIFIED_BY="Bernd Richter">
<SUMMARY MODIFIED="2008-10-22 11:47:38 +0200" MODIFIED_BY="Gudrun Paletta">
<TITLE MODIFIED="2008-10-22 11:47:27 +0200" MODIFIED_BY="Gudrun Paletta">Interventions for the prevention of nutritional rickets in term born children</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-22 11:47:38 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Although only a few studies with different results exist, preventive measures against nutritional rickets appear reasonable in high risk groups until new data become available. </P>
<P>Rickets is a disease which affects the bone of growing children. Calcium and phosphate are important elements which form the bone. In nutritional rickets, initially the availability of calcium is diminished, later disturbances in phosphate occur. The shortage of calcium may be caused by limited intake or limited resorption in the gut. The latter is highly regulated by vitamin D, which can be synthesised from the skin after sun exposure or can be acquired from dietary sources, for example cod liver. Therefore, shortage of calcium, vitamin D or both may lead to nutritional rickets, which is mainly characterized by deformed bones, bone pain, convulsions or delayed development. Since the 1930s supplementation of vitamin D is used for the prevention of rickets in children, mainly in high-income countries; several other measures like supplementation of calcium or longer exposure of the skin to sunlight are also used. Over the time many factors have changed, for example nutrition, which provides calcium, air pollution, through which sun light is absorbed leading to a diminished synthesis of vitamin D in the skin, or social issues, for example child labour, again leading to limited sun exposure. Because of these changes we looked for studies conducted in the last 50 years which investigated patient-relevant outcomes. As patient-relevant outcomes we defined the occurrence of rickets, adverse effects of the intervention, mortality, health-related quality of life and costs.<BR/>Four trials enrolled approximately 1700 participants and lasted between nine months and two years. Study participants were aged from one month to 15 years. There were different results on the occurrence of nutritional rickets in different settings. Adverse effects were investigated in one study only.<BR/>Considering the partial high frequency of nutritional rickets, the obvious way of action of supplementation of vitamin D or calcium and the favourable risk-benefit ratio, preventive measures are reasonable in high risk groups like infants and toddlers. New studies investigating main and side effects of preventive measures against nutritional rickets in different age groups and in different countries are indicated.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-04 12:12:16 +0100" MODIFIED_BY="Bernd Richter">
<ABS_BACKGROUND>
<P>Nutritional rickets is a disease of growing children leading to bone deformities, bone pain, convulsions or delayed motor development. Today, high-incidence of nutritional rickets is mainly found in low-income countries. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of various interventions on the prevention of nutritional rickets in term born children.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Studies were obtained from computerised searches of <I>The Cochrane Library</I>, MEDLINE, EMBASE, LILACS and reference lists of relevant articles. We contacted authors of studies or reviews to obtain further studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Studies were included if they were randomised controlled clinical trials, controlled clinical trials or prospective cohort studies comparing any intervention for the prevention of nutritional rickets in term born children with placebo or no intervention. Minimum duration of the intervention was three months for children under 12 months or six months for children over 12 months. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently extracted data and assessed study quality. Authors of studies were contacted to obtain missing information.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-04 12:12:16 +0100" MODIFIED_BY="Bernd Richter">
<P>Four studies enrolled approximately 1700 participants. Trials lasted between nine months to two years. Three studies were randomised controlled trials, two of which showed a cluster randomised design; one trial probably was a controlled trial with researcher controlled group assignment. In children up to three years of age in Turkey, Vitamin D compared to no intervention showed a relative risk of 0.04 (95% confidence interval (CI) 0 to 0.71). Despite a marked non-compliance, a Chinese trial in children up to three years of age comparing a combined intervention of supplementation of vitamin D, calcium and nutritional counselling showed a relative risk of 0.76 (95% CI 0.61 to 0.95) compared to no intervention. In two studies conducted in older children in China and in France no rickets occurred in both the intervention and control group.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There a only few studies on the prevention of nutritional rickets in term born children. Until new data become available, it appears sound to offer preventive measures (vitamin D or calcium) to groups of high risk, like infants and toddlers; children living in Africa, Asia or the Middle East or migrated children from these regions into areas where rickets is not frequent. Due to a marked clinical heterogeneity and the scarcity of data, the main and adverse effects of preventive measures against nutritional rickets should be investigated in different countries, different age groups and in children of different ethnic origin. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-04 12:13:18 +0100" MODIFIED_BY="Bernd Richter">
<BACKGROUND MODIFIED="2008-11-04 12:12:43 +0100" MODIFIED_BY="Bernd Richter">
<CONDITION MODIFIED="2008-11-04 12:12:43 +0100" MODIFIED_BY="Bernd Richter">
<P>Rickets comprises a group of disorders characterised by defective mineralization and disorganisation of the epiphyseal growth plates. Therefore, rickets is a disease limited to growing children. Mineralisation of the bone matrix is also defective, called osteomalacia.<BR/>The main components of the bone mineral matrix are calcium and phosphate. Rickets is classified depending on the lacking mineral. Nutritional rickets is the main form of calcipenic rickets, nevertheless alterations in phosphate also occur in the course of the disease. The clinical presentation of nutritional rickets depends on the age of the child, it includes soft skull bone, called craniotabes; hypocalcaemic convulsions; typical bone deformities like deformation of the weight-bearing limbs; swelling of the wrist, knee or ankle; swelling of the costochondral junction of the ribs, called rachitic rosary or the deformity of the soft rib cage due to pulling of the diaphragm, called Harrison's sulcus. Furthermore, muscular hypotonia or delayed motor development may occur.<BR/>The biochemical findings of nutritional rickets include a normal or decreased blood level of calcium, a normal, decreased or increased blood level of phosphate as well as elevated blood levels of alkaline phosphatase, parathyroid hormone or both. In vitamin D-deficiency rickets 25-hydroxyvitamin D blood levels are decreased.<BR/>Radiologically, there is an irregular metaphyseal outline like cupping, widening or fraying due to diminished calcification of the growth plate. In younger children the radiological changes can best be visualised in the wrist, in older children the area above and below the knee is most useful (<LINK REF="REF-Pettifor-2005" TYPE="REFERENCE">Pettifor 2005</LINK>; <LINK REF="REF-Shaw-2004" TYPE="REFERENCE">Shaw 2004</LINK>; <LINK REF="STD-Thacher" TYPE="STUDY">Thacher</LINK>).</P>
<P>
<I>
<B>Vitamin D and calcium</B>
<BR/>
</I>In general, nutritional rickets is the result of either calcium or vitamin D deficiency, or both.<BR/>The exposure of the skin to ultraviolet light (wavelengths from 290 to 315 nm, called UV-B) is crucial for the beginning of the endogenous syntheses of vitamin D. Provitamin D<SUB>3</SUB> (7-dehydrocholesterol), stored in the skin, is photolysed by the absorbed energy of UV-B to previtamin D<SUB>3</SUB>. Previtamin D<SUB>3</SUB> converts to vitamin D<SUB>3</SUB> (cholecalciferol) rapidly. Thus, low UV-B irradiation due to northern or southern latitude, high air pollution, short outdoors exposure time, veiling of the skin, the use of sunscreens or high amounts of the skin pigment melanin lower the production of vitamin D<SUB>3</SUB>. As vitamin D<SUB>3</SUB> is synthesised due to sunlight exposure, it is not a vitamin in the strict sense of definition.<BR/>Exogenous sources of vitamin D provide vitamin D<SUB>2</SUB> (ergocalciferol) and vitamin D<SUB>3</SUB>. Very few foods contain a reasonable amount of vitamin D. Human breast milk has only a low concentration of vitamin D, which is an important factor for infants being solely breast fed for a long time.<BR/>Vitamin D, which denotes both vitamin D<SUB>2</SUB> and vitamin D<SUB>3</SUB>, is hydroxylated in the liver to 25-hydroxyvitamin D (calcidiol). A further hydroxylation, mainly in the kidneys, leads to 1,25-dihydroxyvitamin D (calcitriol), the final active form of vitamin D.<BR/>1,25-dihydroxyvitamin D acts via the vitamin D receptor (VDR), an intracellular protein which belongs to the steroid-hormone-thyroid hormone-retinoic acid receptor gene superfamily. Conflicting data exist for the role of polymorphisms of VDR for the pathogenesis of rickets.<BR/>The target of VDR is the vitamin D response element regulating gene transcription which evokes in the intestine the synthesis of proteins necessary for the transfer of calcium from the intestinal lumen to the capillaries. It is assumed that only ten percent of the calcium entry is vitamin D independent. The availability of calcium is lowered by complexation with oxalate or phytate. Inadequate low intake of calcium leads to inactivation of calcidiol.<BR/>A high-fibre diet results in degradation of calcitriol, as does elevated parathyroid hormone resulting from hypocalcaemia.<BR/>In state of dietary calcium deficiency, vitamin D also interacts with VDR in bone tissue. The thereby induced maturation of osteoclasts leads to dissolving of bone tissue and thus, release of calcium. It is not clear whether there is a direct effect of vitamin D on bone formation, too.<BR/>There are many other actions of vitamin D besides the regulation of calcium homeostasis, for example regulation of cell growth and apoptosis being associated with several forms of cancer. Furthermore, the modulation of immune reactions is associated with autoimmune diseases like type 1 diabetes mellitus or multiple sclerosis. There are influences on the functions of muscles and the nervous system, too (<LINK REF="REF-Bronner-2003" TYPE="REFERENCE">Bronner 2003</LINK>; <LINK REF="REF-Dusso-2005" TYPE="REFERENCE">Dusso 2005</LINK>; <LINK REF="REF-Pettifor-2003" TYPE="REFERENCE">Pettifor 2003</LINK>; <LINK REF="REF-Thacher-2003" TYPE="REFERENCE">Thacher 2003</LINK>).</P>
<P>
<I>
<B>Frequency of nutritional rickets<BR/>
</B>
</I>To describe the frequency of nutritional rickets in term infants three aspects have to be considered. First, due to different diagnostic criteria reported frequencies are not directly comparable (<LINK REF="REF-Peach-1984" TYPE="REFERENCE">Peach 1984</LINK>). Secondly, frequency is extremely time dependent. In the 1920s and 1930s the prevalence of nutritional rickets was between 75% to 98% in Europe and the United States of America based on autopsies, clinical examination or radiographs (<LINK REF="REF-Chesney-2001" TYPE="REFERENCE">Chesney 2001</LINK>). Thirdly, three groups have to be distinguished:<BR/>
</P>
<UL>
<LI>Infants with fair skin</LI>
<LI>Infants with intermediate or dark skin living in their indigenous area</LI>
<LI>Infants with intermediate or dark skin living in an area with lower UV-B irradiation than in their indigenous area</LI>
</UL>
<P>In the first group nutritional rickets mostly is due to pure vitamin D deficiency. Only few recent data for incidence or prevalence are known. For example, in a study in the West Midlands, United Kingdom, in which the overall incidence was 7.5 per 100,000 children under five years, only 1 of 24 children with rickets (defined by radiological changes or hypocalcaemic convulsions) was classified as 'white' which approximates an incidence of 0.4 per annum per 100,000 children under five years (<LINK REF="REF-Callaghan-2006" TYPE="REFERENCE">Callaghan 2006</LINK>). In Turkey, 10% of children from 3 to 36 months had clinical and biochemical changes consistent with rickets (<LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK>). Fifteen per cent of children under one year showed biochemical changes in Greece (<LINK REF="REF-Lapatsanis-1968" TYPE="REFERENCE">Lapatsanis 1968</LINK>), nine per cent of children between 12 and 24 months showed radiological changes in the United Kingdom (<LINK REF="REF-Richards-1968" TYPE="REFERENCE">Richards 1968</LINK>).<BR/>In the second group, nutritional rickets may be due to calcium or vitamin D deficiency. For example, in Nigeria nine per cent of children between six months and three years showed clinical signs of rickets (<LINK REF="REF-Pfitzner-1988" TYPE="REFERENCE">Pfitzner 1988</LINK>). In Tibet, 66% of children over 24 months showed clinical features of rickets (<LINK REF="REF-Harris-2001" TYPE="REFERENCE">Harris 2001</LINK>).<BR/>Children of immigrants or immigrated infants represent the third group. The study in the West Midlands, United Kingdom mentioned above showed an incidence for children of south Asian ethnic origin of 38 and for children of black African or African-Caribbean ethnic origin of 95 per annum per 100,000 children under the age of 5 five years (<LINK REF="REF-Callaghan-2006" TYPE="REFERENCE">Callaghan 2006</LINK>).</P>
<P>
<I>
<B>Development of prevention<BR/>
</B>
</I>Although early descriptions of rickets reach back to antiquity, rickets became more frequent in the 17<SUP>th</SUP> century. During and after the industrialisation in Europe and North America, rickets was a disease of high frequency, presumably because of the changing socio-economic and nutritional circumstances. Cod liver oil was first used traditionally, in the 19<SUP>th</SUP> century the specific action against rickets was noted. After its discovery vitamin D was used in different formes for the treatment and later the prevention of rickets (<LINK REF="REF-Rajakumar-2003" TYPE="REFERENCE">Rajakumar 2003</LINK>).<BR/>In the 20<SUP>th</SUP> century rickets was considered to be a disease which affects children up to approximately five years of age. After the recognition of rickets in older immigrant children in the United Kingdom, cross-sectional studies showed that native children were also affected. Therefore, preventive measures need had to be considered (<LINK REF="REF-Cooke-1973" TYPE="REFERENCE">Cooke 1973</LINK>).<BR/>Because of the relationship of sun light and synthesis of vitamin D, rickets were considered not be prevalent in tropical areas. Reports starting in the 1930s showed that rickets was a frequent disease in these regions and still is today. That is why preventive measures need to be considered in these areas as well (<LINK REF="REF-Jelliffe-1968" TYPE="REFERENCE">Jelliffe 1968</LINK>; <LINK REF="REF-Thacher-2006" TYPE="REFERENCE">Thacher 2006</LINK>).</P>
<P>
<B>Diagnostic criteria used for the review</B>
<BR/>There are no generally accepted diagnostic criteria for nutritional rickets. Therefore, we extracted data according to authors' definition of rickets. The different diagnostic criteria may produce significant variability in the clinical characteristics of the people with rickets included as well as in the results obtained. We planned to explore these differences in a sensitivity analysis.<BR/>Ideally, three diagnostic criteria would be encountered:<BR/>1. Clinical signs or radiological findings of rickets.<BR/>2. Elevated blood levels of alkaline phosphatase, parathyroid hormone or both.<BR/>3. Exclusion of disorders mimicking nutritional rickets (like phosphopenic rickets, vitamin D deficiency or lack of calcium due to gastrointestinal or renal diseases, inborn disorders of vitamin D or calcium metabolism).</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-10-22 11:51:10 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Interventions for the prevention of nutritional rickets include supplementation of vitamin D, for example on a daily basis, as a "stossprophylaxis" (intermittent application of large amounts) or in fortified food, especially milk; calcium supplementation or advice on sun exposure.</P>
</INTERVENTION>
<THEORY MODIFIED="2008-10-22 11:51:25 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Since paucity of calcium is crucial in nutritional rickets it is essential to increase the resorption of calcium. Therefore, there are three possibilities of intervention: First, increasing the calcium intake; secondly, increasing the endogenous syntheses of vitamin D; thirdly, increasing the vitamin D intake.<BR/>
<B>
<BR/>Adverse effects of the intervention</B>
<BR/>Reported adverse effects of vitamin D supplementation are hypercalcaemia or nephrocalcinosis (<LINK REF="REF-Markestad-1987" TYPE="REFERENCE">Markestad 1987</LINK>; <LINK REF="REF-R_x00f6_nnefarth-2000" TYPE="REFERENCE">Rönnefarth 2000</LINK>). Overexposure of the skin to sunlight may lead to skin cancer.<BR/>
</P>
</THEORY>
<IMPORTANCE MODIFIED="2008-10-22 11:51:38 +0200" MODIFIED_BY="Gudrun Paletta">
<P>There are still many countries in Africa, Asia and the Middle East with high frequency of nutritional rickets. Furthermore, the incidence of rickets seems to be reincreasing in countries with a formerly low incidence. The latter might be linked to reduced acceptance of preventive measures. Considering the worldwide high burden of nutritional rickets leads to the question whether there are any effective measures for the prevention of nutritional rickets. As far as we know there is no systematic review, meta-analysis or health-technology assessment report about the prevention of nutritional rickets.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of various interventions on the prevention of nutritional rickets in term born children.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-04 12:11:43 +0100" MODIFIED_BY="Bernd Richter">
<SELECTION_CRITERIA MODIFIED="2008-10-22 11:53:01 +0200" MODIFIED_BY="Gudrun Paletta">
<CRIT_STUDIES>
<P>Randomised, quasi-randomised and non-randomised controlled clinical trials and prospective cohort studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Healthy term born children or children with diseases not increasing the risk of developing rickets.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>
<B>
<I>Intervention</I>
</B>
<BR/>Any intervention used for the prevention of nutritional rickets like vitamin D supplementation via tablets, liquids or fortified food; calcium supplementation, advice to get more sunlight or combinations of these interventions.</P>
<P>
<B>
<I>Comparison</I>
</B>
<BR/>Placebo or no intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-22 11:53:01 +0200" MODIFIED_BY="Gudrun Paletta">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-22 11:52:28 +0200" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>occurrence of rickets;</LI>
<LI>adverse effects.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-22 11:53:01 +0200" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>all-cause mortality;</LI>
<LI>quality of life (ideally measured by a validated instrument);</LI>
<LI>costs.</LI>
</UL>
<P>

</P>
<SUBSECTION>
<HEADING LEVEL="5">Covariates, effect modifiers and confounders</HEADING>
<UL>
<LI>different groups of children (mentioned under 'Frequency of nutritional rickets');</LI>
<LI>compliance;</LI>
<LI>nutrition (for example phytate or oxalate intake);</LI>
<LI>age.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Timing of outcome assessment</HEADING>
<P>We had planned to include prospective studies only if observation lasted longer than three years. This observation period was considered to be long enough to definitely exclude rickets clinically, radiologically, or both. As we failed to identify these, we adapted the criteria: for children younger than 12 months of age, observation had to last three months or longer; for children older than 12 months of age, observation had to last six months or longer.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-22 12:27:31 +0200" MODIFIED_BY="Gudrun Paletta">
<ELECTRONIC_SEARCHES MODIFIED="2008-10-22 12:27:31 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We searched the following electronic databases:<BR/>
</P>
<UL>
<LI>
<I>The Cochrane Library</I> (issue 3, 2006);</LI>
<LI>MEDLINE (via OVID interface, until August 2006);</LI>
<LI>EMBASE (via OVID interface, until August 2006);</LI>
<LI>LILACS (until August 2006).</LI>
</UL>
<P>We also searched the metaRegister of Clinical Trials (www.controlled-trials.com/mrct) to identify ongoing studies.</P>
<P>Studies published in any language were included. For details on the search strategy see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. This strategy was used for MEDLINE and adapted for the other databases.</P>
<P>
<B>Reference lists<BR/>
</B>We tried to identify additional studies by searching the reference lists of included trials and reviews identified.</P>
<P>
<B>Correspondence<BR/>
</B>We contacted authors of studies and reviews as experts in the field to obtain additional references or unpublished trials.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-04 12:11:43 +0100" MODIFIED_BY="Bernd Richter">
<STUDY_SELECTION MODIFIED="2008-11-04 12:11:43 +0100" MODIFIED_BY="Bernd Richter">
<P>First, one author (CL) scanned the title or abstract, or both sections of every record retrieved to eliminate all records not dealing with nutritional rickets or unequivocally not reporting comparative studies. Secondly, both authors scanned the title or abstract, or both sections of the selected records to determine which studies require further assessment. All potentially relevant articles were investigated as full text. Interrater agreement for study selection was measured using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). Consensus about variation in rated records was reached by discussion. An adapted QUOROM (quality of reporting of meta-analyses) flow chart of study selection (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>) is attached (see (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-04 12:06:42 +0100" MODIFIED_BY="Bernd Richter">
<P>For studies fulfilling the inclusion criteria, both authors independently extracted relevant population and intervention characteristics using standard data extraction sheets. Consensus about differently extracted data was reached by discussion. Any relevant missing information on the study was sought from the authors of the study. For details, please see 'Characteristics of included studies' and <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2,</LINK> <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-10-22 12:00:43 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Both authors independently assessed the methodological quality of each included study, differences were resolved by discussion. For randomised controlled trials we used quality criteria specified by <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK> and by <LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>, for other prospective comparative studies quality criteria specified by <LINK REF="REF-Downs-1998" TYPE="REFERENCE">Downs 1998</LINK> and by <LINK REF="REF-Deeks-2003" TYPE="REFERENCE">Deeks 2003</LINK>. We planned to explore the influence of individual quality criteria in a sensitivity analysis (see under 'sensitivity analyses'). Inter-rater agreement was calculated using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-10-22 12:00:55 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We decided to base the analysis on dichotomous data (here, rickets yes/no) expressed as relative risks (RR) with 95% confidence intervals (CI). <B>
<I>
<BR/>
</I>
</B>
</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2008-10-22 12:01:13 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We planned to address cluster-randomised studies or studies with multiple interventions for meta-analyses specifically.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-10-22 12:01:58 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Relevant missing data were obtained or tried to obtain from authors. Evaluation of important numerical data such as screened, eligible and randomised children as well as intention-to-treat and per-protocol population was carefully performed. Drop-outs, misses to follow up and withdrawn study participants were investigated.</P>
<SUBSECTION>
<HEADING LEVEL="4">Dealing with duplicate publications</HEADING>
<P>In the case of duplicate publications and companion papers of a primary study, we planned to maximise yield of information by simultaneous evaluation of all available data. In cases of doubt, the original publication (usually the oldest version) was planned to obtain priority.</P>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-10-22 12:02:13 +0200" MODIFIED_BY="Gudrun Paletta">
<P>In case of relevant heterogeneity due to clinical, methodological or statistical issues, study result were not planned to be combined in a meta-analysis. Heterogeneity was planned to be identified and quantified using the &#967;²-test with significance being set &#945; = 0.1 and the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), the latter describing the percentage of total variation across studies that is due to heterogeneity rather than chance. I<SUP>2</SUP>-values of 50% or more indicate relevant heterogeneity. We planned to identify possible sources of heterogeneity by evaluating individual study characteristics and subgroup and sensitivity analyses.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-10-22 12:02:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We planned to use funnel plots to assess small study bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-10-22 12:02:55 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Data were planned to be summarised statistically if they were available, sufficiently similar and of sufficient quality. Statistical analysis was planned to be performed according to the statistical guidelines referenced in the newest version of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>). Pooled results were planned to be analysed using primarily the DerSimonian and Laird random-effects method (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). For preventive measures, the relative risk of adverse outcome, here occurrence of rickets, is the appropriate summary statistic (<LINK REF="REF-Deeks-2002" TYPE="REFERENCE">Deeks 2002</LINK>).<BR/>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-10-22 12:03:09 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Subgroup analyses were planned to be only performed if one of the primary outcome parameters demonstrated statistically significant differences between treatment groups.<BR/>The following subgroup analyses were planned:<BR/>
</P>
<UL>
<LI>using the three groups described in the section 'Description of the disease';</LI>
<LI>breast milk nutrition during infancy;</LI>
<LI>veiling of the mother during pregnancy or nursing;</LI>
<LI>mode of administration of the intervention.</LI>
</UL>
<P>
<BR/>Subgroup analyses were planned to be mainly used to explore heterogeneity due to clinical, methodological or statistical issues and as a hypothesis generating exercise.<BR/>
</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-10-22 12:03:19 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We planned to perform sensitivity analyses in order to explore the influence of the following factors on effect size:<BR/>
</P>
<UL>
<LI>repeating the analysis excluding unpublished studies;</LI>
<LI>repeating the analysis taking account of study quality, as specified above;</LI>
<LI>repeating the analysis excluding any very long or large studies to establish how much they dominate the results;</LI>
<LI>repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country, no primary consensus regarding study selection.</LI>
</UL>
<P>
<BR/>The robustness of the results was planned to be tested by repeating the analysis using different measures of effects size (risk difference, odds ratio etc.) and different statistic models (fixed- and random-effects models).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-04 12:13:08 +0100" MODIFIED_BY="Bernd Richter">
<STUDY_DESCRIPTION MODIFIED="2008-11-04 12:13:08 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Results of the search<BR/>
</B>The initial search identified 7542 records, from these, 221 full papers were identified for further examination. The other studies were excluded on the basis of their abstracts because they were not relevant to the question under study (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for details of the amended QUOROM (quality of reporting of meta-analyses) statement). After screening the full text of the selected papers, four studies finally met the inclusion criteria.</P>
<P>
<B>Assessment of inter-rater agreement</B>
<BR/>Inter-rater agreement for study selection, that is qualifying a study as 'potentially relevant' was 74%.</P>
<P>
<B>Missing data</B>
<BR/>We contacted or tried to contact all authors of included studies:<BR/>
<LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK> was contacted for clarification of the mode of group allocation. We received no response.<BR/>
<LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK> was contacted for clarification if there was a thorough clinical examination regarding the clinical signs of rickets and if participants with rickets were discovered. Authors provided additional data.<BR/>
<LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> was contacted for clarification if the two participants who showed radiological signs of rickets at the beginning of the study were the same as the two participants showed radiological signs of rickets at the end of the study. We received no response.<BR/>
<LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> was contacted for providing the number of participants in each group and the number of participants with rickets in each group. Authors provided additional data. Specific data for participants who were compliant with vitamin D and calcium supplementation were not available.</P>
<P>
<B>Excluded studies</B>
<BR/>Two studies had to be excluded after careful evaluation of the full publication. Reasons for exclusion was high risk for bias due to high or marked different attrition rates (for details see table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
<P>
<B>Characteristics of included studies</B>
<BR/>For details see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>, <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
<P>
<I>
<B>Interventions</B>
<BR/>Comparisons<BR/>
</I>
<LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK> investigated vitamin D versus no intervention. <LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK> studied milk fortified with calcium versus milk fortified with calcium and cholecalciferol versus no intervention. <LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> investigated vitamin D versus placebo. <LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> studied a combined intervention of supplementation of vitamin D and calcium plus parents' nutritional counselling.</P>
<P>
<I>Number of study centres<BR/>
</I>Three of the four included studies had one study centre only, <LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> reported four study centres.</P>
<P>
<I>Country and location<BR/>
</I>
<LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK> and <LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> were performed in China, <LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK> in Turkey and <LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> in France.</P>
<P>
<I>Setting<BR/>
</I>
<LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK> recruited children from the community. <LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK> was a cluster study with recruitment from schools. <LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> recruited from hospital patients. <LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> was also a cluster study, recruiting from different villages.<BR/>
<I>
<BR/>Treatment before study</I>
<BR/>No publication informed about treatment before the intervention.</P>
<P>
<I>
<B>Methods</B>
<BR/>Duration of the intervention<BR/>
</I>Included studies had a treatment duration ranging from six months to two years.</P>
<P>
<I>Duration of follow up<BR/>
</I>The follow up in <LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> lasted 6 to 30 months, including a post-intervention follow up up to 6 months. In the remaining studies duration of treatment and follow up was identical, there was no post-intervention follow up.</P>
<P>
<I>Language of publication</I>
<BR/>Three of the four included studies were published in English, <LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> in French.</P>
<P>
<I>
<B>Participants</B>
<BR/>Who participated<BR/>
</I>Study participants were aged from one months to 15 years, <LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK> recruited only girls.</P>
<P>
<I>Inclusion and exclusion criteria<BR/>
</I>In three of four included studies, participants were described as 'healthy'. <LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> recruited from hospital patients, but excluded patients with gastrointestinal or nephrological diseases or other conditions involved in the metabolism of vitamin D or phosphorus. <LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK> excluded all children with clinical signs of nutritional rickets, <LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> excluded children with heart malformations.</P>
<P>
<I>Relevant diagnostic criteria<BR/>
</I>
<LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK> used a stepwise approach with clinical signs leading to radiological and biochemical assessment. <LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> used radiological criteria. <LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK> and <LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> used clinical signs only.</P>
<P>
<I>Co-morbidities<BR/>
</I>No study described co-morbidities, although <LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> recruited hospital patients.</P>
<P>
<I>Co-medications</I>
<BR/>No study described co-medications.<BR/>
<I>
<B>
<BR/>Outcomes</B>
<BR/>Primary, secondary and additional outcomes<BR/>
</I>
<LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK> and <LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> used the occurrence of rickets as the only outcome parameter. <LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> measured calcium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone and alkaline phosphatases in blood and radiographed wrists without distinction of primary or secondary outcomes. <LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK> investigated bone mineral content, bone area, bone mineral density, total body composition, plasma 25-hydroxyvitamin D, intact parathyroid hormone, blood calcium, calcium/creatinine ratio in urine, weight, length, sitting height, clinical signs of rickets without distinction of primary or secondary outcomes.<I>
<BR/>
</I>
</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-04 12:07:55 +0100" MODIFIED_BY="Bernd Richter">
<P>For details on methodological quality of included studies see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>
<B>Overview</B>
<BR/>All included studies were of parallel design.<BR/>Interrater agreement for the key quality indicators was 100%.</P>
<P>
<B>Randomisation and allocation concealment<BR/>
</B>
<LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK> was probably as a controlled clinical trial with researcher determined group assignment. The other three studies were randomised controlled clinical trials, two of which used a cluster randomisation design (<LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK>; <LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK>). None of the randomised controlled clinical trials provided details about the method of randomisation or the concealment of allocation.<BR/>
<B>
<BR/>Blinding<BR/>
</B>
<LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK> and <LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> used no placebo, so participants were not blinded. <LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> was described as 'double-blind' without further details. <LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK> gave no details regarding blinding. No publications reported checking of blinding.</P>
<P>
<B>Definition of primary endpoint and secondary endpoints<BR/>
</B>No study provided an explicit definition of the primary endpoint. However, <LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK> and <LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> investigated one endpoint only .</P>
<P>
<B>Power calculation<BR/>
</B>None of the included studies reported power calculation.</P>
<P>
<B>Intention-to-treat and per-protocol analyses, missing data<BR/>
</B>
<LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK> did not report summary statistics, therefore we calculated relative risks on an intention-to-treat basis. <LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> provided count data, relative risk was based on analysed patients. In the remaining studies, there were no quantitative data for rickets in both, intervention and control groups.<BR/>For missing data, imputation was not used for relevant outcomes in any of the included studies.</P>
<P>
<B>Screened and randomised patients<BR/>
</B>None of the included studies reported number of screened patients.</P>
<P>
<B>Discontinuing participants and attrition rates<BR/>
</B>All included studies reported the number of discontinuing participants, only <LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK> provided details of the reasons for discontinuation.</P>
<P>
<B>Compliance measures<BR/>
</B>
<LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK> and <LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> controlled adherence by direct observation of intake of the interventional medication.</P>
<P>
<B>Funding<BR/>
</B>Two of the four studies reported funding. <LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> was funded by an non-governmental organisation, <LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK> was funded by an organisation which receives money from diary levies and the Australian government.</P>
<P>
<B>Publication status<BR/>
</B>All included studies were published in regular issues of journal with a peer review system.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-22 12:26:13 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Baseline characteristics</B>
<BR/>For details of baseline characteristics see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>
<B>Primary outcomes</B>
</P>
<P>For details of primary outcomes see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
<P>
<B>
<I>Occurrence of rickets<BR/>
</I>
</B>In two of the four included studies, rickets neither occurred in the intervention nor the control group (<LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK>; <LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK>).<BR/>
<LINK REF="STD-Beser-1994" TYPE="STUDY">Beser 1994</LINK> recruited children aged 3 to 36 months at inclusion in a rural community in Turkey aiming for a complete survey. After exclusion of children with clinical signs of rickets, the remaining children were divided in two groups with similar socio-economic and cultural background and nourishment levels. The intervention group received oral vitamin D 400 IU per day for 12 months, the control group received no intervention. At the end of the study a stepwise approach was used for the diagnosis of nutritional rickets: clinical signs led to biochemical and radiological assessment. In the intervention group rickets was not observed in any of the 302 children. In the control group 14 children out of 374 developed rickets. The relative risk (RR) was 0.04 (95% confidence interval (CI) 0 to 0.71).<BR/>
<LINK REF="STD-Strand-2002_x002f_2003" TYPE="STUDY">Strand 2002/2003</LINK> was a cluster-randomised study in rural China. The intervention consisted of the promotion of exclusive breastfeeding from birth, supplementation of solid foods at the age of five months, weaning at 12 to 18 months, oral vitamin D 300 IU/day during the first 12 months, oral calcium 378 mg/day from age five months to 24 months. At the timing of outcome assessment, children were aged 6 to 30 months meaning that some children still received the intervention. Outcome assessment used clinical parameters. In the intervention group 100 out of 183 children showed clinical signs of nutritional rickets, in the control group 13 out of 46 children. The RR was 0.76 (95% CI 0.61 to 0.95). There was a pronounced non-compliance to the recommended supplementation of vitamin D and calcium.</P>
<P>
<B>
<I>Adverse effects of the interventions<BR/>
</I>
</B>
<LINK REF="STD-Duhamel-2000" TYPE="STUDY">Duhamel 2000</LINK> stated, that no hypercalcaemia was observed. The remaining studies did not investigate adverse effects.</P>
<P>
<B>Secondary outcomes</B>
<BR/>For details of secondary outcomes see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
<P>
<B>
<I>Mortality<BR/>
</I>
</B>No study investigated mortality.</P>
<P>
<B>
<I>Quality of life<BR/>
</I>
</B>No study investigated health-related quality of life.</P>
<P>
<B>
<I>Costs<BR/>
</I>
</B>No study investigated costs.</P>
<P>
<B>Heterogeneity<BR/>
</B>Due to obvious clinical heterogeneity and only a few included studies, we did not perform a meta-analysis.</P>
<P>
<B>Subgroup analyses </B>
<BR/>Not performed due to lack of data.</P>
<P>
<B>Sensitivity analyses</B>
<BR/>Not performed due to lack of data.</P>
<P>
<B>Publication and small study bias</B>
<BR/>Not performed due to insufficient amount of data.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-04 12:13:18 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Summary of the main findings<BR/>
</B>This systematic review shows that there are only few studies on the prevention of clinical or radiological diagnosed nutritional rickets in term born children. Because of the clinical heterogeneity in nutritional rickets itself as well as between the included studies neither a quantitative nor a qualitative data synthesis is reasonable. Vitamin D prevented rickets in children up to three years of age in Turkey. In China, a combined intervention of vitamin D, calcium and nutritional counselling led to a decreased risk of rickets in children up to three years of age, although there was a marked non-compliance. In a study conducted in prepubertal girls in China rickets did not occur in both control or intervention groups who received calcium or calcium plus vitamin D. In France, rickets were not observed in children of about twelve years of age who received vitamin D or placebo.<BR/>Adverse effects were only addressed in one study, in which no hypercalcaemia was observed after administration of vitamin D. No study investigated health-related quality of life or economic costs of the interventions.</P>
<P>
<B>Limitations of the review<BR/>
</B>We focused on a minimum duration of intervention of three months for children under twelve months of age and of six months for children over twelve months of age. Theoretically, studies of a shorter duration could demonstrate a significant impact, but this is thought to be highly unlikely.<BR/>Although the prevention of nutritional rickets has a long history and was studied many years ago, we decided to include studies conducted in the last 50 years only because of the substantial changes of life circumstances like nutritional issues, sun exposure or environmental factors such as air pollution.<BR/>Since preventive measures were introduced to prevent nutritional rickets with its 'classical' clinical and radiological features we used this definition for our review. We did not include rickets diagnosed solely on biochemical data.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>We discovered only a few published studies of interventions for the prevention of nutritional rickets in term born children. Considering pathophysiological aspects, the high frequency of nutritional rickets and the favourable risk-benefit ratio we conclude that it is reasonable to offer preventive measures (vitamin D or calcium) to all children up to two years of age. Further groups of high risk are children living in Africa, Asia or the Middle East and migrants from these regions into areas where rickets is not frequent.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Due to a marked clinical heterogeneity and scarcity of data, the current indication for prevention of nutritional rickets should be investigated in different countries, different age groups and in children of different ethnic origin. Besides patient-oriented outcomes on efficacy, adverse effects of the chosen intervention should be studied. Especially with reference to vitamin D, controlled prospective studies should investigate both short-time effects on occurrence of nutritional rickets and long-term effects on occurrence of autoimmune diseases or cancer.<BR/> </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank the Department of General Pediatrics, University Children's Hospital, Moorenstr. 5, 40225 Duesseldorf, GERMANY (Dr Thomas Meissner) for its support to finish this review.</P>
<P>For help with translations we thank (in alphabetical order) Markéta Benesová, Daniel Bereczki, Barbara and Frank Brüderle, Monica Durosca, Hanna Kauffmann, Marta Kollenda, Morgane Legendre, Regina Miltner, Andrey Solodarenko, translation bureau Semantik and Maria Zangmeister.<BR/>We thank the following experts and authors of studies for their responses to our enquiries (in alphabetical order): Uri Alon, Annie Anderson, Christopher Bates, Abdullah Bereket, Xueqin Du, Ghada El-Hajj Fuleihan, Philip Fischer, Catherine Gordon, Frank Greer, Zeev Hochberg, Marjo Lehtonen-Veromaa, Michael Levine, John Pettifor, Willem Proesmans, Frank Rauch, Eckhard Schönau, Nicolas Shaw, Mark Strand, Tom Thacher, Jan-Maarten Wit, Zvi Zadik and Kathy Zu. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>CHRISTIAN LERCH: protocol development, searching for trials, quality assessment of trials, data extraction, data analysis, review development<BR/>THOMAS MEISSNER: protocol development, quality assessment of trials, data extraction, review development</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-11-04 12:13:22 +0100" MODIFIED_BY="Bernd Richter">
<TABLE COLS="4" ROWS="4">
<TR>
<TD>
<P>Background</P>
</TD>
<TD>
<P>details added, arrangement changed</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Types of studies</P>
</TD>
<TD>
<P>prospective cohort studies, controlled clinical trials, randomised controlled clinical trials</P>
</TD>
<TD>
<P>randomised controlled trials preferred, if not identified also controlled clinical trials, cohort studies, case-control studies</P>
</TD>
<TD>
<P>to minimise bias</P>
</TD>
</TR>
<TR>
<TD>
<P>Time of outcome assessment</P>
</TD>
<TD>
<P>intervention or follow-up for children under 12 months of age three months at least, for children over 12 months of age six months at least</P>
</TD>
<TD>
<P>minimum duration of prospective studies three years</P>
</TD>
<TD>
<P>we did not identify studies lasting three years</P>
</TD>
</TR>
<TR>
<TD>
<P>Selection of studies</P>
</TD>
<TD>
<P>in the first step, only one author (CL) checked title, abstract or both to determine publications dealing with nutritional rickets and obviously not reporting non-comparative data</P>
</TD>
<TD>
<P>every step of studies selection was planned to be done by two authors</P>
</TD>
<TD>
<P>approximately 8000 records retrieved, efforts to reduce work load</P>
</TD>
</TR>
</TABLE>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-04 12:09:09 +0100" MODIFIED_BY="Bernd Richter">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Beser-1994" NAME="Beser 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beser E, Cakmakci T</AU>
<TI>Factors affecting the morbidity of vitamin D deficiency and primary protection</TI>
<SO>East African Medical Journal</SO>
<YR>1994</YR>
<VL>71</VL>
<PG>358-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Du-2004" NAME="Du 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du X, Zhu K, Trube A, Zhang Q, Ma G, Hu X et al</AU>
<TI>School-milk intervention trial enhances growth and bone mineral accretion in Chinese girls aged 10-12 years in Beijing</TI>
<SO>British Jounral of Nutrition</SO>
<YR>2004</YR>
<VL>92</VL>
<PG>159-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duhamel-2000" NAME="Duhamel 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;D3 tieferstellen&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duhamel JF, Zeghoud F, Sempé M, Boudailliez B, Odièvre M, Laurans M et al</AU>
<TI>Prevention of vitamin D deficiency during adolescence: interventional multicenter study on the biological effects of repeated dosis of 100,000 IU of vitamin D3</TI>
<TO>Prophylaxie de la carence en vitamine D chez l'adolscent et le préadolscent. Étude interventionnelle multicentrique sur les effets biologiques d'un apport répété de 100 000 UI de vitamine D3</TO>
<SO>Archives de Pédiatrie</SO>
<YR>2000</YR>
<VL>7</VL>
<PG>148-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Strand-2002_x002f_2003" NAME="Strand 2002/2003" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Jahreszahl des ID&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strand MA, Peng G, Zhang P, Lee G</AU>
<TI>Preventing rickets in locally appropriate ways: a case report from north China</TI>
<SO>International Quarterly of Community Health Education</SO>
<YR>2002/2003</YR>
<VL>21</VL>
<PG>297-322</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Nguema_x002d_Asseko-2005" NAME="Nguema-Asseko 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;gabones im Titel tats&amp;#228;chlich klein geschrieben&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nguema-Asseko B, Ganga-Zandzou PS, Ovono F, Lendoye E, Lemamy GJ, Akendengue B et al</AU>
<TI>Vitamin D status in gabonese children</TI>
<TO>Statut et besoins en vitamine D chez le nourisson au Gabon</TO>
<SO>Archives de pédiatrie</SO>
<YR>2005</YR>
<VL>12</VL>
<PG>1587-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Thacher" NAME="Thacher" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Thacher TD, Fischer PR, Isichei CO, Zoakah AI, Pettifor JM</AU>
<TI>Prevention of nutritional rickets in Nigerian children with dietary calcium supplementation</TI>
<SO>E-mail from Dr Thacher, 17.11.2004</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-04 12:09:09 +0100" MODIFIED_BY="Bernd Richter">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-04 12:09:09 +0100" MODIFIED_BY="Bernd Richter">
<REFERENCE ID="REF-Bronner-2003" NAME="Bronner 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bronner F</AU>
<TI>Mechanisms of intestinal calcium absorption</TI>
<SO>Journal of Cellular Biochemistry</SO>
<YR>2003</YR>
<VL>88</VL>
<PG>387-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Callaghan-2006" NAME="Callaghan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Callaghan AL, Moy RJD, Booth IW, Debelle G, Shaw NJ</AU>
<TI>Incidence of symptomatic vitamin D deficiency</TI>
<SO>Archive of Diseases in Childhood</SO>
<YR>2006</YR>
<VL>91</VL>
<PG>606-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chesney-2001" NAME="Chesney 2001" TYPE="JOURNAL_ARTICLE">
<AU>Chesney RW</AU>
<TI>Vitamin D deficiency and rickets</TI>
<SO>Reviews in Endocrine &amp; Metabolic Disorders</SO>
<YR>2001</YR>
<VL>2</VL>
<PG>145-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1960" NAME="Cohen 1960" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J</AU>
<TI>A coefficient of agreement for nominal scales</TI>
<SO>Educational and Psychological Measurement</SO>
<YR>1960</YR>
<VL>20</VL>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooke-1973" NAME="Cooke 1973" TYPE="JOURNAL_ARTICLE">
<AU>Cooke WT, Swan CH, Asquith P, Melikian V, McFeely WE</AU>
<TI>Serum alkaline phosphatase and rickets in urban schoolchildren</TI>
<SO>British Medical Journal</SO>
<YR>1973</YR>
<VL>1</VL>
<NO>5849</NO>
<PG>324-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2002" NAME="Deeks 2002" TYPE="JOURNAL_ARTICLE">
<AU>Deeks JJ</AU>
<TI>Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1575-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2003" MODIFIED="2008-10-22 12:34:00 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Deeks 2003" TYPE="JOURNAL_ARTICLE">
<AU>Deeks JJ, Dines J, D'Amico R, Sowden AJ, Sakarovitch C, Song F et al</AU>
<TI>Evaluating non-randomised intervention studies</TI>
<SO>Health Technology Assessment</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>27</NO>
<PG>iii-x, 1-173</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Downs-1998" NAME="Downs 1998" TYPE="JOURNAL_ARTICLE">
<AU>Downs SH, Black N</AU>
<TI>The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions</TI>
<SO>Journal of Epidemiology and Community Health</SO>
<YR>1998</YR>
<VL>52</VL>
<PG>377-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dusso-2005" NAME="Dusso 2005" TYPE="JOURNAL_ARTICLE">
<AU>Dusso AS, Brown AJ, Slatopolsky E</AU>
<TI>Vitamin D</TI>
<SO>American Journal of Physiology: Renal Physiology</SO>
<YR>2005</YR>
<VL>289</VL>
<PG>F8-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-2001" NAME="Harris 2001" TYPE="JOURNAL_ARTICLE">
<AU>Harris NS, Crawford PB, Yangzom Y, Pinzo L, Gyaltsen P, Hudes M</AU>
<TI>Nutritional and health status of Tibetan children living at high altitude</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<PG>341-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" MODIFIED="2008-11-04 12:09:09 +0100" MODIFIED_BY="Bernd Richter" NAME="Higgins 2006" TYPE="CONFERENCE_PROC">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]</TI>
<SO>The Cochrane Library, Issue 4</SO>
<YR>2006</YR>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jelliffe-1968" NAME="Jelliffe 1968" TYPE="BOOK">
<AU>Jelliffe DB</AU>
<SO>Infant nutrition in the subtropics and tropics</SO>
<YR>1968</YR>
<EN>2nd</EN>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lapatsanis-1968" MODIFIED="2008-10-22 12:34:07 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Lapatsanis 1968" TYPE="JOURNAL_ARTICLE">
<AU>Lapatsanis P, Deliyanni V, Doxiadis S</AU>
<TI>Vitamin D deficiency rickets in Greece</TI>
<SO>The Journal of Pediatrics</SO>
<YR>1968</YR>
<VL>73</VL>
<PG>195-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Markestad-1987" NAME="Markestad 1987" TYPE="JOURNAL_ARTICLE">
<AU>Markestad T, Hesse V, Siebenhuner M, Jahreis G, Aksnes L, Plenert W et al</AU>
<TI>Intermittent high-dose vitamin D prophylaxis during infancy: effect on vitamin D metabolites, calcium, and phosphorus</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1987</YR>
<VL>46</VL>
<PG>652-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF</AU>
<TI>Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9193</NO>
<PG>1896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peach-1984" NAME="Peach 1984" TYPE="JOURNAL_ARTICLE">
<AU>Peach H</AU>
<TI>A critique of survey methods used to measure the occurence of osteomalacia and rickets in the United Kingdom</TI>
<SO>Community Medicine</SO>
<YR>1984</YR>
<VL>6</VL>
<PG>20-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pettifor-2003" NAME="Pettifor 2003" TYPE="BOOK_SECTION">
<AU>Pettifor JM</AU>
<TI>Nutritional rickets</TI>
<SO>Pediatric Bone</SO>
<YR>2003</YR>
<PG>541-65</PG>
<ED>Glorieux FH, Pettifor JM, Jüppner H</ED>
<PB>Academic Press</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pettifor-2005" NAME="Pettifor 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pettifor JM</AU>
<TI>Rickets and vitamin D deficiency in children and adolescents</TI>
<SO>Endocrinology and metabolism clinics of North America</SO>
<YR>2005</YR>
<VL>34</VL>
<PG>537-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pfitzner-1988" NAME="Pfitzner 1988" TYPE="JOURNAL_ARTICLE">
<AU>Pfitzner MA, Thacher TF, Pettifor JM, Zoakah AI, Lawson JO, Isichei CO et al</AU>
<TI>Absence of vitamin D deficiency in young Nigerian children</TI>
<SO>The Journal of Pediatrics</SO>
<YR>1998</YR>
<VL>133</VL>
<PG>740-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rajakumar-2003" NAME="Rajakumar 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rajakumar K</AU>
<TI>Vitamin D, cod-liver oil, sunlight and rickets: a historical perspective</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>112</VL>
<PG>e132-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richards-1968" MODIFIED="2008-10-22 12:34:12 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Richards 1968" TYPE="JOURNAL_ARTICLE">
<AU>Richards IDG, Sweet EM, Arneil GC</AU>
<TI>Infantile rickets persists in Glasgow</TI>
<SO>Lancet</SO>
<YR>1968</YR>
<VL>1</VL>
<PG>803-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-R_x00f6_nnefarth-2000" NAME="Rönnefarth 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rönnefarth G, Misselwitz J, Members of the Arbeitsgemeinschaft für pädiatrische Nephrologie</AU>
<TI>Nephrocalcinosis in children: a retrospective survey</TI>
<SO>Pediatric Nephrology</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>1016-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shaw-2004" NAME="Shaw 2004" TYPE="BOOK_SECTION">
<AU>Shaw NJ, Kershaw M</AU>
<TI>Vitamin D deficiency in children</TI>
<SO>Recent Advances in Paediatrics 21</SO>
<YR>2004</YR>
<PG>85-100</PG>
<ED>David TJ</ED>
<PB>Royal Society of Medicine Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thacher-2003" NAME="Thacher 2003" TYPE="JOURNAL_ARTICLE">
<AU>Thacher TD</AU>
<TI>Calcium-deficiency rickets</TI>
<SO>Endocrine Development</SO>
<YR>2003</YR>
<VL>6</VL>
<PG>105-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thacher-2006" NAME="Thacher 2006" TYPE="JOURNAL_ARTICLE">
<AU>Thacher TD, Fisher PR, Strand MA, Pettifor JM</AU>
<TI>Nutritional rickets around the world: causes and future directions</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>2006</YR>
<VL>26</VL>
<PG>1-16</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-04 12:13:55 +0100" MODIFIED_BY="Bernd Richter">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-04 12:13:55 +0100" MODIFIED_BY="Bernd Richter" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-04 12:13:22 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Beser-1994">
<CHAR_METHODS>
<P>DURATION OF INTERVENTION:<BR/>12 months<BR/>DURATION OF FOLLOW-UP:<BR/>12 months<BR/>LANGUAGE OF PUBLICATION:<BR/>English</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>WHO PARTICIPATED:<BR/>Turkish children, aged 3 to 36 months at inclusion<BR/>INCLUSION CRITERIA:<BR/>prior exclusion of rickets<BR/>EXCLUSION CRITERIA:<BR/>see above<BR/>DIAGNOSTIC CRITERIA:<BR/>stepwise approach: clinical signs led to radiological and biochemical assessment<BR/>CO-MORBIDITIES:<BR/>not stated<BR/>CO-MEDICATIONS:<BR/>not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>NUMBER OF STUDY CENTRES:<BR/>1<BR/>COUNTRY/ LOCATION:<BR/>Turkey, rural<BR/>SETTING:<BR/>community<BR/>INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY):<BR/>Vitamin D 400 IU/day per os<BR/>CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY):<BR/>none<BR/>TREATMENT BEFORE STUDY:<BR/>not stated<BR/>TITRATION PERIOD:<BR/>not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-04 12:13:22 +0100" MODIFIED_BY="Bernd Richter">
<P>PRIMARY OUTCOME(S):<BR/>occurrence of rickets<BR/>SECONDARY OUTCOMES:<BR/>none</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>STATED AIM OF STUDY: <BR/>to assess primary prevention of rickets</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-04 12:13:53 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Du-2004">
<CHAR_METHODS>
<P>DURATION OF INTERVENTION:<BR/>2 years<BR/>DURATION OF FOLLOW-UP:<BR/>2 years<BR/>LANGUAGE OF PUBLICATION: <BR/>English</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>WHO PARTICIPATED:<BR/>Chinese girls, aged 10 years at inclusion<BR/>INCLUSION CRITERIA:<BR/>free of any disease that might affect bone development<BR/>EXCLUSION CRITERIA:<BR/>see above<BR/>DIAGNOSTIC CRITERIA:<BR/>clinical assessment<BR/>CO-MORBIDITIES:<BR/>not stated<BR/>CO-MEDICATIONS:<BR/>not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-04 12:13:53 +0100" MODIFIED_BY="Bernd Richter">
<P>NUMBER OF STUDY CENTRES:<BR/>1<BR/>COUNTRY/ LOCATION:<BR/>China, urban<BR/>SETTING:<BR/>cluster study with primary schools as cluster<BR/>INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY):<BR/>I1: fortified milk with calcium 560 mg/school day, averaged 245 mg/day<BR/>I2: fortified milk with calcium 560 mg plus vitamin D3 200 (during first third of study) or 320 (during second and third third of study) IU/school day, averaged calcium 245 mg plus vitamin D3 133 IU/day<BR/>CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY):<BR/>none<BR/>TREATMENT BEFORE STUDY:<BR/>not stated<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PRIMARY OUTCOME(S):<BR/>bone mineral content, bone area, bone mineral density, total body composition, 25-hydroxyvitamin D in blood, intact parathyroid hormone in blood, blood calcium in blood, calcium/creatinine ratio in urine, weight, length, sitting height, clinical signs of rickets <BR/>SECONDARY OUTCOMES:<BR/>no distinction made between primary and secondary outcomes</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>STATED AIM OF STUDY: <BR/>to examine the effects of providing a dietary supplement of a small volume of milk to Chinese pre-pubertal girls in Beijing<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Duhamel-2000">
<CHAR_METHODS>
<P>DURATION OF INTERVENTION:<BR/>9 months<BR/>DURATION OF FOLLOW-UP:<BR/>9 months<BR/>LANGUAGE OF PUBLICATION:<BR/>French</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>WHO PARTICIPATED:<BR/>French children, aged 10 to 15 years<BR/>INCLUSION CRITERIA:<BR/>hospital admission<BR/>EXCLUSION CRITERIA:<BR/>gastrointestinal or nephrological diseases or other conditions involved in the metabolism of vitamin D or phosphate<BR/>DIAGNOSTIC CRITERIA:<BR/>clinical, radiological and biochemical assessment<BR/>CO-MORBIDITIES:<BR/>not stated<BR/>CO-MEDICATIONS:<BR/>not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>NUMBER OF STUDY CENTRES:<BR/>4<BR/>COUNTRY/ LOCATION:<BR/>France, urban<BR/>SETTING:<BR/>hospital based<BR/>INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY):<BR/>vitamin D3 100,000 IU at beginning, after 3 and after 6 month, per os <BR/>CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY):<BR/>placebo<BR/>TREATMENT BEFORE STUDY:<BR/>not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PRIMARY OUTCOME(S):<BR/>calcium in blood and urine, phosphorus in blood and urine, alkaline phosphatases in blood, intact parathyroid hormone in blood, 25-hydroxyvitamin D in blood, radiographs of the wrist<BR/>SECONDARY OUTCOMES:<BR/>no distinction made between primary and secondary outcomes</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>STATED AIM OF STUDY: <BR/>to follow the changes in calcium status and 25-hydroxyvitamin D and parathyroid hormone levels under repeated dosis of vitamin D in winter</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-04 12:13:55 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Strand-2002_x002f_2003">
<CHAR_METHODS>
<P>DURATION OF INTERVENTION:<BR/>2 years<BR/>DURATION OF FOLLOW-UP:<BR/>up to 2.5 years<BR/>LANGUAGE OF PUBLICATION:<BR/>English</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>WHO PARTICIPATED:<BR/>Chinese children, age at inclusion approximately 1 month<BR/>INCLUSION CRITERIA:<BR/>not stated<BR/>EXCLUSION CRITERIA:<BR/>not stated (however, children with congenital heart defects were excluded)<BR/>DIAGNOSTIC CRITERIA:<BR/>clinical assessment<BR/>CO-MORBIDITIES:<BR/>not stated<BR/>CO-MEDICATIONS:<BR/>not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>NUMBER OF STUDY CENTRES:<BR/>1<BR/>COUNTRY/ LOCATION:<BR/>China, rural<BR/>SETTING:<BR/>cluster study with villages as clusters<BR/>INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY):<BR/>promoting of exclusive breastfeeding from birth, supplementation of solid foods at age 5 months, weaning at 12 to 18 months, vitamin D 300 IU/day per os during the first 12 months, calcium 378 mg/day per os from age 5 months to 24 months <BR/>CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY):<BR/>none<BR/>TREATMENT BEFORE STUDY:<BR/>not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-04 12:13:55 +0100" MODIFIED_BY="Bernd Richter">
<P>PRIMARY OUTCOME(S):<BR/>occurrence of rickets<BR/>SECONDARY OUTCOMES:<BR/>none stated</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>STATED AIM OF STUDY: <BR/>to determine the effectiveness of this rickets prevention programme</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Nguema_x002d_Asseko-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>high risk for bias due to marked differences in discontinuation rates between groups after three months (intervention 9%, comparison 29%, overall 19%), after six months discontinuation rate 34%</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thacher">
<CHAR_REASON_FOR_EXCLUSION>
<P>high risk for bias due to discontinuation 40%</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Beser-1994">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Du-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Duhamel-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Strand-2002_x002f_2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-04 12:13:59 +0100" MODIFIED_BY="Bernd Richter">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-11-04 12:13:59 +0100" MODIFIED_BY="Bernd Richter" NO="1">
<TITLE MODIFIED="2008-10-22 13:01:40 +0200" MODIFIED_BY="Gudrun Paletta">Risk of bias</TITLE>
<TABLE COLS="5" ROWS="66">
<TR>
<TH>
<P>Characteristic</P>
</TH>
<TH>
<P>Beser 2004</P>
</TH>
<TH>
<P>Du 2004</P>
</TH>
<TH>
<P>Duhamel 2000</P>
</TH>
<TH>
<P>Strand 2002/2003</P>
</TH>
</TR>
<TR>
<TD>
<P>Intervention 1 (I1) / intervention 2 (I2) / control 1 (C1)</P>
</TD>
<TD>
<P>I1. vitamin D 400 IU/day per os<BR/>C1. no placebo or other intervention<BR/>
</P>
</TD>
<TD>
<P>I1: fortified milk, averaged calcium 245 mg/day per os<BR/>I2: fortified milk, averaged calcium 245 mg/day per os, vitamin D3 133 IU/day per so<BR/>C1: no placebo or other intervention</P>
</TD>
<TD>
<P>I1. vitamin D3 100,000 IU every 3 months per os<BR/>C1. placebo</P>
</TD>
<TD>
<P>I1: promoting of exclusive breastfeeding from birth, supplementation of solid foods at age 5 months, weaning at 12 to 18 months, vitamin D 300 IU/day per os during the first 12 months, calcium 378 mg/day per os from age 5 months to 24 months<BR/>C1: no placebo or other intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>Randomised controlled clinical trial (RCT)<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Controlled clinical trial<BR/>
</P>
</TD>
<TD>
<P>?<BR/>(presumed Y)</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Prospective cohort study</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Method of randomisation (specify)<BR/>
</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Unit of randomisation (individuals, cluster - specify)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>cluster (pupils of matched 3 x 3 schools)</P>
</TD>
<TD>
<P>individuals</P>
</TD>
<TD>
<P>cluster (children of 16 matched villages )</P>
</TD>
</TR>
<TR>
<TD>
<P>Randomisation stratified for centres<BR/>
</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Randomisation ratio</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?<BR/>(intervention group: 14 villages, control group: 2 villages)</P>
</TD>
</TR>
<TR>
<TD>
<P>Concealment of allocation (specify)<BR/>
</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Study population representative of population</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?<BR/>(recruited from hospital)</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Method of selection of controls (specify) (*)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Patients in different groups form same population (*)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Exposed/unexposed over same period of time (*)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Ascertainment of group determination (specify) (*)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Ascertainment of outcome (specify)</P>
</TD>
<TD>
<P>direct measurement</P>
</TD>
<TD>
<P>direct measurement</P>
</TD>
<TD>
<P>direct measurement</P>
</TD>
<TD>
<P>direct measurement</P>
</TD>
</TR>
<TR>
<TD>
<P>Stated blinding (open; single, double, triple blind)<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>double</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Actual blinding: participant/parents<BR/>
</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Actual blinding: caregiver / treatment administrator<BR/>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Actual blinding: outcome assessor<BR/>
<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Actual blinding: others<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Blinding checked: participant<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Blinding checked: caregiver / treatment administrator<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Blinding checked: outcome assessor</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Primary endpoint defined<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of primary endpoint(s)<BR/>
</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of secondary endpoints<BR/>
</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>Total [n] of endpoints<BR/>
<BR/>
</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>12<BR/>(no distinction made between primary and secondary outcomes)</P>
</TD>
<TD>
<P>8<BR/>(no distinction made between primary and secondary outcomes)</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>Prior publication of study design<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Power calculation<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] participants per group calculated<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Intention-to-treat analysis (ITT)<BR/>
</P>
</TD>
<TD>
<P>Y<BR/>(no summary statistic in analysis)</P>
</TD>
<TD>
<P>Y<BR/>(no summary statistic for rickets in analysis)</P>
</TD>
<TD>
<P>Y<BR/>(no summary statistic for rickets in analysis)</P>
</TD>
<TD>
<P>N<BR/>(based on analysed patients)</P>
</TD>
</TR>
<TR>
<TD>
<P>Per-protocol-analysis<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N<BR/>(based on analysed patients)</P>
</TD>
</TR>
<TR>
<TD>
<P>ITT defined</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Dealing with missing data</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?<BR/>(imputing for birth weight which is not relevant for this review)</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of screened participants (I1/ I2 / C1 / total)<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of randomised/included participants (for primary endpoint)<BR/>
</P>
</TD>
<TD>
<P>I1: 302<BR/>C1: 374</P>
</TD>
<TD>
<P>I1: 238<BR/>I2: 260<BR/>C1: 259</P>
</TD>
<TD>
<P>I1: 32<BR/>C1: 34<BR/>
</P>
</TD>
<TD>
<P>Total: 259</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of participants finishing the study<BR/>
</P>
</TD>
<TD>
<P>I1: 293<BR/>C1: 369</P>
</TD>
<TD>
<P>I1: 209<BR/>I2: 242<BR/>C1: 247</P>
</TD>
<TD>
<P>I1: 32<BR/>C1: 31</P>
</TD>
<TD>
<P>Total: 245</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of patients analysed (for primary endpoint)<BR/>
</P>
</TD>
<TD>
<P>no summary statistic provided</P>
</TD>
<TD>
<P>no summary statistic for rickets provided</P>
</TD>
<TD>
<P>no summary statistic for rickets provided</P>
</TD>
<TD>
<P>I1: 183<BR/>C1: 46<BR/>Total: 229</P>
</TD>
</TR>
<TR>
<TD>
<P>Description of discontinuing participants</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Drop-outs (reasons explained)<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Withdrawals (reasons explained)<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Losses-to-follow-up (reasons explained)<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of participants who discontinued<BR/>
</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] discontinuation rate<BR/>
</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation rate similar between groups</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Differences [n] calculated to analysed patients<BR/>
<BR/>
</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Adjustment for multiple outcomes / repeated measurements<BR/>
</P>
</TD>
<TD>
<P>N/A<BR/>no summary statistic provided</P>
</TD>
<TD>
<P>Y<BR/>no summary statistic for rickets provided</P>
</TD>
<TD>
<P>N/A<BR/>no summary statistic provided</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Baseline characteristics: clinically relevant differences<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y<BR/>(more preterm born children in intervention group)</P>
</TD>
</TR>
<TR>
<TD>
<P>Treatment identical (apart from intervention)<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Compliance measured<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Other important covariates measured (specify)<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Co-morbidities measured<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Co-medications measured<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Different length of follow-up (taken into account) (*)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Loss of study patients taken into account</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Specific doubts about study quality<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Funding: commercial<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Funding: non-commercial<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Publication status: peer review journal<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Publication status: journal supplement<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Publication status: abstract<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Publication status: other<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Symbols &amp; abbreviations: Y = yes; N = no; ? = unclear; N/A = not applicable; I = intervention; C = control<BR/>(*) for prospective cohort studies only</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2008-11-04 12:11:17 +0100" MODIFIED_BY="Bernd Richter">
<FIGURE FILENAME="figure1.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-11-04 12:11:17 +0100" MODIFIED_BY="Bernd Richter" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>QUOROM (quality of reporting of meta-analyses) flow-chart of study selection</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfQAAALDAQAAAADLOs+vAAAPmUlEQVR42u3df2wb130A8HTBVmxZ
kwJZYqdLTKzOmrWF42Vp7Q2xzXXBHDSLmxSbLESKRKRepFRsyCCexFiU+IY6nTPEtf5wXQeRLSJO
NjdiqVsrSweLI99gJTZiVZZrl2RMinzwFFmJqONZP+5O4une25HUT+uH+d55lpUcAVu0wk++x3tf
vnv3fXePtxFDj6u3md70pje96U1vetOb3vSmN73pTW9605uext927eN2Kj+54AUTVH7hqzGVV416
XiQQ5p9HMaT3AZGQKY8wQ/w2Hwpwguzj5WBxOSzGUgudhz5ba0Bo/yUvw+gVGCfBNK1HjQFBgVmP
YZLaB3XPCyMxfsRftNMXIVKavv2Umb/Y2l806Fcy//IC59+ApqdSmiX+jCe0HhaL5aIQ02pCij1R
ZveXUfp2RU2CiZFL7WizPZT4YRBR5m8o64VY94CiuEMJJ7XnirTylvcuCD9o578ZLrrDn3CsuvZf
Ua9gqCfO5fsbmL2eeNxEHc/a/8Y6JJXPrFVY48fgt7kTm38nsns9vnLey+hfO33s3l28smUfa/sh
g+2PVn3+CmQC6M2PU/rzVzC9T0x1ftnnI8RD662JFBmU7DVahm8jHdQeWxNxBQmvyJpyUiHN5HvU
HtmUUiGGNFnYTc7Sbz9Qnxg//fDZ345/f7iGxNYaaT/FYPuLqzL/PJ+AO/4rvRZMWk+y+ZTejQ3o
zwLPsHk70eSIe4Ts3snmfwG+9HL0zVf22r/M5rsIcT2ujuDnKxjfv4jljvjIj9UvM7af+Pk9/mb3
38QZC2kw4jswDAFWDzxqyOM9wuqx1SPDpvO/NOCvBtLoE+btt3pwJHn+AGBvP3Hl2n/h+bNG5fFi
5+8Lf/mF69YPtGU3ClP5Rd4CoPKdSu5cWv+DmDxSpk+s2HwsHK4Kugeb26pQseyvV8McnT8dQYMS
QZ5WhCRZJapE6ZMRVCWNdnpaO3U/Xk/vo9GqoJpp4WtRXNYHCLR+zg+VZf8t/ICAm5o/Rv2kR5v9
tX5SrkI6HwezXtU9pvQKqa/y13LSgUy/ZBdKYDO992puRatSBGIfwvAbkHb/1e8V6vZpd+T8V0K1
lD4G6qveK+G0DZl+Yhd2hkooPVrwSyovTfdXKoX/n8V6S9b4hvPXRRRNmdPzUnoR6WN5ZaoPBNS+
/+3tu9dcPtRoPTA5PvkKOP7IQ3Q+7CviosKuKsKrNZofxLoBnZd8RXCN4LrDqqiy7jt76H0oKlRX
IUhy8TVKL49WgEqhHVkRntBageJ2ra7+y7i3GvJa9vV/cNrK6rtffGSdNT0GmePbt3r+NTnA7Lud
f9bkTSqA1UvZ+E0/Z95/YjDQ5G0asq5Q+xsd/xkdf1KMf01vetObnowz+gVd1RcNnr8bnf+evLn1
J16c2v0oSmamIil8YJ5niC8IyO6S9TPtIiB5sA9Qzt9BQfS6n5bbHMkiIFbiFDhH69PIrcf3xItJ
zlPGD/3HELIXj7Q54juJVIsHAdP8ozI9UlcBZvVa1k+uuvpn7vVwqgwHrGw+9xAlXOGl9VykJSIk
QxGSkLkarQbRem/Wo1CkR+sX5J/QezGCc14fNIo1k5uo/U/Xok3Cn/KbDuPaB2uIi37/XTuBSO3h
SuaP0f5zcpmh6s04fpjHb9Ob3vSmv4X8LTh/Ruc7c0dlBU9PbQZo589mPJf7RYrSJ0fb11sPDb9p
vfedB7YNX9nis9L5zg1tIVQtO1DEn8YkAZsR5fZvbDtGlJwXQxMabLZQeq4NIrfiSEb8OAk16vin
LiYVGFCPILcArW4c8lHWn+cPjTSy+urHucf0hdUEKywe53323IbSn/7qF/69b0tFw4GKDfcNH2za
dWUflZcUDnICKeHbGoUazL/Exfjr+7nzR1GV1/+HMf7EOuG8zNc9mqTbfonX44vZ+AF/hczXcxme
7v137f6rhIIH+HNXio9mAtB1Ba3K/DHqs5dksXlx2n+rh8VfeejYI/ssD/1gHLRzLD7MZbr1Y0bJ
ye+weUk81UMALDkJOu5i8QqXSRCMSvd854TI4mWX/Jiy8VviHhAQ2doPz1crnX90x+/JZU5KCxq/
mPMnpje96U1fsJfAisTHK3z/pOH6+76Zi19XZv4nkBptfUvUuo8eiZJ44n8TpIly+7PzRyA/f6RV
YB+gvf9NEC3uJ+S2O3uLwOXs/M8BWj+Ui5+bP6pgmD9yj36z0Sl1NyUiRH0gI4AQS/vPzh8RY/NH
2mq8/h4RVVcNfSy+N4y7G8WPMg7vCab4vhJoS9gG5TSSO1m8Wt7+XAK8hfH5dJzNt9oSZBA3oSYm
vz+5/77yM6//ZQj9Wx/b/s+f5EPm9stL68rkzwTtgeBGzx+Zx2/Tm970pv/seLzgXGScyhutPxmu
f3Wh/JM+Rj91AwcnMnrYZfG5/MXHB1h9DDW6Aj3vPsa6/TGScgXIcZXRfxiz+Yr9tndvZ/RG2+8z
4rV6Mn1fLJvXMCy4fi7O81CKhFNHizzeguvXaJ63CLEgTuwInS/Yz7//yCImg1irTiMn2/Zb+yPh
wUSR43yDmX9M/pp7GOnjzwiYvR+M2r9euXvt3oP37/nR+wc7ZXpvEUvFtAbsNd4gjD3A4LnHxbQA
7C97f3IyzvD+Lc5SzaP7mpgUjK1hbz9grP0zt0j+Ud4/s2D8YM4f3dTx2w2//oeu/QyP/zpnSjLZ
TKoHhP76H5K/dijrNGqfvNi+p0f9Wk/moq2yDVeDTWeu66+CufE3tslQSdmGum0wQiQgUl4/hJzt
NWT4E9vlX5Vvk3Xft+T1N4vW7zW0oa2dkBQSN5SFsvHJkvEXXb9BOzV6eg8Z+RiNPr99zb3kA3Bs
yes3Fq1fUfQ/M/V7QFCu1RRKP1W/F6evA6f2faN3v35m5MEX3rEctN79qPU1D+X25+r3hCvtQAJw
RBCf88MfFerz9fvJjY//Xc5brn5P92f6Gwv2/qFc/JLaOfEvPFBw/Hz9nrgcChgFzs0gmd1/F9Uk
KNAv2v4X1sQM+YuXC95+o/lHbCJR5t5DQOkhynr9P7/vYvJ7n23Yes+x71ssh/jF/PXGD2pwpyMs
QZvzb5Vr4s99S6eW/Pyrv3rGcc8979icT6fn+96eOqF84ClQd9Q7PPnRkusfqP6djng4oMdPKHO9
xWcLbPUBpSigVY3d+bF3SR8u9Qa+1l/qfPq1zfN8qvyxoO+JM/+0RasdwzELbftbUmXZ+Hy1Wu8c
u3OZ7V8qf4bSvcIvuiLOuujRMTwAmPJPXWQ0vYgPEawu49XreQ9R9R9X9wOm/CfkK+ODbzzaKb+3
pFeW89haQjId6Oz9ny7p0XX8eCZzd5d2aZ6P3y+6KuKj2xLntN6fK9ZlPc50JM7eHZzrLUK8rAMl
hPpSQFqLAmi59++YqI0/1nX1wLz8uYxe+DF5XgToqe/ujQbo80+MlzWhjXp8Fw4UdSDq/FGPDLlc
gVFP9v1HVBtD/mkG+08ar+kvFrPdKGLIv2c5JLzk2lb5YO9Rq4XeWz28M1w9mODCagLOxtfmnYcs
lz8u3qntSJIN1V2Jt+duvzRZmK/R49cnE/6wWjbrU0W1YwV5Al7l7+v/+74t6+/52Zztd+/AY78H
Ctz/YGH7uSU8Nm7AH/lg3RgG/+/HX23R8WfuiaUQv/j49xap3yADvhdP9J4DVU4YTMGT7SKtt/rq
a1KJkJ9DQAApmXr9JEsKTKrPEoEjoiBWyTyDl9VL7B4O4Zf3n97mqLRYBMsbaxsY2w/m/nYSyOax
NffDy+pXMv9EEsiPyHK9ALV3r9/U0bpLfOjbn2Km+HYx0hH2l5OowOa70nJHWCjFivAlJn84rccX
EY4yep5b23Hh4QFljaCZ9WcGr2Z/KGL22qbs55Dax93PCbCyW/4wdTDtqrJS93+Dmr0aKb5UsWDX
VIG+/3Nb7Tu2KqmuUsHej7qPU3u7Zq/XlJQ9osdv7KaOD9/6xx99sG7z0NiHQuPZioet9O2nsbdf
bv23UUp/A9efG74R+YunKn9ZCum9Uoc2wxcq3R+n9VPAX1Mfv0gmBFNJoURTbcXBjpbD9J8frGSI
UDqhgmot4/cyxOczWLAJWU84J733NATWbai8Oklqtv60ld5fs6wCvQervP8cNeY5g/54nzH/7nqD
8TsNxn/08338vAE+M/svpvGrasDDmE+o8oPaMV9UeytYQ3/81ThhUAHurZBozT0eet+vCVW6D+q+
pYc+vvVjv/AkB2oln6K1B/+FZf/N/EZma7+ZDuDc6sw/PX3uMhRfA4jdN//uG/9tNeDr2nxb34bs
HgR9GjTgmw81B43Ev9ntP74y8Re9fl2brU7pH9zct6It5Rddf0mbW50jmKX+BX1PEhvxEV+x9KTf
pi25fvnU+nW4hdPP2LWp9cBy5x/PqYi4CVd6MeYHy/jAlIf5+e5ZX5z3tvh1fL9g+2FxuqU5Ougr
qpUy0JHv/5p35rafKxZKlvX59evSLT4+k9qRJhl0jnL+LLd+Xd7X65446Hx+/brBFl8001zmkaj9
zDOFqX4563vm+xCczmSRqX6a9UruTv7DTP6rxw5/MrL+/V13WhS2+EFvqlpLBNPPOJf3l5fyDbrv
D6Zty8ffJy7hOWdK4hJc+pk1y/oTX1+y/qwW0n68YMwvE58uf268B7M1UMhQfycg+9Vo+e4TFl5/
n+p/9//mqT37e/78Pz/q3b/9kb9hqD8H4vUOXmqC5YGkyFC/9uX8IW8g66/Sezss1X044C6H5ZrM
Vv8VZxuByQODfiXHfziAp+Y/IFv86ZVP8nfW0dcvArZPw5xfehWwxY/9mrijgAuqj7N6i+5PBlXG
+JkASkVFv8QaXzVev72Fzn/N9UtMb/pC/Wfh+l84s4yVKBKR/vt34PQBOHcUovTJi+08/AfhaCoY
d9T1vCT+hrL+n1v/Tw06BVktC9iaFZHy+6uQs+0Ydgf/UFjzxj9bbZwyROuz8QNBTza+mo2/kc6f
Gj29ftvXP3iz776fbX8VvacMbaby13x/UIYYmz+iXj/wBnx/EcqljQrZPMqlHZj6LtTsZUB0vtFz
CdmSzkt/1Aqf6h1WqT0CNoxEq1jityl26YsM/rdN6C5rQ0kQnfljCROG+GkErM4SP+Ld1b9P7eOe
C2g3ch5qbEWRXmkcrPr7X+junzWPf6Y3velNb3rTfz680fX/xldm+42uHzWxzFCrEG94/TWoaPll
4gfYvK9N6hip2dBzF6P3F01GRKlZcUYZvTQZUaTj6MVi5viyIB1XXryd0f/J5b8e3f4XZ5zKirSf
0fwxun6l0fUzqR+mN73pTW9605ve9KY3velNb3rTm970pjf9sv7/ACfAOc1uK+juAAAAAElFTkSu
QmCC
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-10-22 12:41:04 +0200" MODIFIED_BY="Gudrun Paletta">
<APPENDIX ID="APP-01" MODIFIED="2008-10-22 11:43:33 +0200" MODIFIED_BY="Gudrun Paletta" NO="1">
<TITLE MODIFIED="2008-10-22 11:42:09 +0200" MODIFIED_BY="Gudrun Paletta">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-22 11:43:33 +0200" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD>
<P>Unless otherwise stated, search terms were free text terms; exp = exploded MeSH: Medical Subject Heading (Medline medical index term); the dollar sign ($) stands for any character(s); the question mark (?) = substitute for one or no characters; tw = text word; pt = publication type; sh = MeSH: Medical subject heading (MEDLINE medical index term); adj = adjacency.<BR/>
<BR/>The following MEDLINE search strategy using the OVID database will be adapted for use with the other databases.<BR/>
<BR/>(1) exp RICKETS/<BR/>(2) rickets.tw.<BR/>(3) rachiti$.tw.<BR/>(4) exp OSTEOMALACIA/<BR/>(5) osteomalac$.tw.<BR/>(6) exp VITAMIN D Deficiency/<BR/>(7) (vitamin$-D adj defic$).tw.<BR/>(8) (defic$ adj vitamin$-D).tw.<BR/>(9) or/1-8<BR/>
<BR/>(10) exp CALCIUM/<BR/>(11) exp Vitamin D/<BR/>(12) exp Ergocalciferols/<BR/>(13) exp CHOLECALCIFEROL/<BR/>(14) (calcium or vitamin$ D).tw.<BR/>(15) sunlight$.tw.<BR/>(16) exp SUNLIGHT/<BR/>(17) or/10-16<BR/>
<BR/>(18) exp Dietary Supplements/<BR/>(19) supplement$.tw.<BR/>(20) (defic$ or poor$ or poverty or lack$ or limit$).tw.<BR/>(21) 18 or 19 or 20<BR/>(22) 17 and 21<BR/>(23) 22 or 9<BR/>
<BR/>(24) exp Infant, Newborn/<BR/>(25) exp INFANT/<BR/>(26) exp CHILD/<BR/>(27) (infant$ or newborn$ or child$).tw.<BR/>(28) or/24-27<BR/>(29) 23 and 28<BR/>
<BR/>(30) exp Infant, Premature/<BR/>(31) preterm$ or prematur$) adj infant$).tw.<BR/>(32) 30 or 31<BR/>(33) 29 not 32<BR/>(34) limit 33 to human<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-10-22 11:43:48 +0200" MODIFIED_BY="Gudrun Paletta" NO="2">
<TITLE MODIFIED="2008-10-22 11:42:26 +0200" MODIFIED_BY="Gudrun Paletta">Baseline characteristics</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-22 11:43:48 +0200" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="5" ROWS="13">
<TR>
<TH>
<P>Characteristic</P>
</TH>
<TH>
<P>Beser 1994</P>
</TH>
<TH>
<P>Du 2004</P>
</TH>
<TH>
<P>Duhamel 2000</P>
</TH>
<TH>
<P>Strand 2002/2003</P>
</TH>
</TR>
<TR>
<TD>
<P>Intervention 1 (I1) / intervention 2 (I2) / control 1 (C1)</P>
</TD>
<TD>
<P>I1: vitamin D 400 IU/day per os<BR/>C1: no placebo or other intervention</P>
</TD>
<TD>
<P>I1: fortified milk, averaged calcium 245 mg/day per os<BR/>I2: fortified milk, averaged calcium 245 mg/day per os, vitamin D3 133 IU/day per so<BR/>C1: no placebo or other intervention</P>
</TD>
<TD>
<P>I1: vitamin D3 100,000 IU every three months per os<BR/>C1: placebo</P>
</TD>
<TD>
<P>I1: promoting of exclusive breastfeeding from birth, supplementation of solid foods at age 5 months, weaning at 12 to 18 months, vitamin D 300 IU/day per os during the first 12 months, calcium 378 mg/day per os from age 5 months to 24 months<BR/>C1: no placebo or other intervention</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] (I1/ I2 / C1 / total)</P>
</TD>
<TD>
<P>I1: 302<BR/>I2: 374<BR/>Total: 676</P>
</TD>
<TD>
<P>I1: 238<BR/>I2: 260<BR/>C1: 259<BR/>Total: 757</P>
</TD>
<TD>
<P>I1: 32<BR/>C1: 34<BR/>Total: 66<BR/>
</P>
</TD>
<TD>
<P>I1: 183<BR/>C1: 46<BR/>Total: 229<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Age at inclusion [mean (SD)]</P>
</TD>
<TD>
<P>Total: 3 months to 36 months (range)</P>
</TD>
<TD>
<P>Total: 10 years</P>
</TD>
<TD>
<P>Total: 12.5 years (1.5)</P>
</TD>
<TD>
<P>Total: approximately 1 month</P>
</TD>
</TR>
<TR>
<TD>
<P>Sex [n,%]<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>female: 100</P>
</TD>
<TD>
<P>male: 51<BR/>female: 49</P>
</TD>
<TD>
<P>I1: male 50<BR/>female 50<BR/>C1: male 63<BR/>female 37</P>
</TD>
</TR>
<TR>
<TD>
<P>Ethnic groups [%]</P>
</TD>
<TD>
<P>?<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Socioeconomic status</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Location<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Turkey, villages around Akcaabat</P>
</TD>
<TD>
<P>China, Beijing</P>
</TD>
<TD>
<P>France, northern Loire</P>
</TD>
<TD>
<P>China, Shanxi Province</P>
</TD>
</TR>
<TR>
<TD>
<P>Start of study [year]<BR/>
<BR/>
</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>1999</P>
</TD>
<TD>
<P>1996</P>
</TD>
<TD>
<P>1997</P>
</TD>
</TR>
<TR>
<TD>
<P>Length of follow-up<BR/>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>24 months</P>
</TD>
<TD>
<P>9 months</P>
</TD>
<TD>
<P>6 to 30 months<BR/>
<BR/>(mean age at outcome assessment:<BR/>I1: 18.2 months<BR/>C1: 15.6 months)<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Outcome assessment</P>
</TD>
<TD>
<P>first clinical, than biochemical and radiological assessment</P>
</TD>
<TD>
<P>clinical assessment</P>
</TD>
<TD>
<P>radiological assessment</P>
</TD>
<TD>
<P>clinical assessment<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Notes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Number of participants: Two children who showed radiological changes at the beginning of the study and at the end of the study were excluded for this review. Thus, number of participants was corrected.</P>
</TD>
<TD>
<P>Participants:<BR/>included a small amount of preterm born children (which is assumed as a risk factor for rickets), proportion in intervention group higher than on control group (8.2% vs. 4.3%)<BR/>Number of participants: based on analysed participants, total of enrolled 259, total of study completed 245<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Symbols &amp; abbreviations: ? = unclear<BR/>I = intervention; C = control<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-10-22 11:44:04 +0200" MODIFIED_BY="Gudrun Paletta" NO="3">
<TITLE MODIFIED="2008-10-22 11:42:53 +0200" MODIFIED_BY="Gudrun Paletta">Primary outcome data</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-22 11:44:04 +0200" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="3" ROWS="6">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Occurence of rickets</P>
</TH>
<TH>
<P>Adverse effects</P>
</TH>
</TR>
<TR>
<TD>
<P>Beser 1994<BR/>
<BR/>I1: vitamin D 400 IU/day per os<BR/>C1: no placebo or other intervention</P>
</TD>
<TD>
<P>I1: 0/302<BR/>C1: 14/374<BR/>
</P>
</TD>
<TD>
<P>not investigated<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Du 2004<BR/>
<BR/>I1: fortified milk, averaged calcium 245 mg/day per os<BR/>I2: fortified milk, averaged calcium 245 mg/day per os, vitamin D3 133 IU/day per so<BR/>C1: no placebo or other intervention</P>
</TD>
<TD>
<P>I1: 0/238<BR/>I2: 0/260<BR/>C1: 0/259</P>
</TD>
<TD>
<P>not investigated</P>
</TD>
</TR>
<TR>
<TD>
<P>Duhamel 2000<BR/>
<BR/>I1: vitamin D3 100,000 IU every 3 months per os<BR/>C1: placebo</P>
</TD>
<TD>
<P>I1: 0/32<BR/>C1: 0/34</P>
</TD>
<TD>
<P>hypercalcaemia:<BR/>I1: 0/32<BR/>C1: 0/34</P>
</TD>
</TR>
<TR>
<TD>
<P>Strand 2002/2003<BR/>
<BR/>I1: promoting of exclusive breastfeeding from birth, supplementation of solid foods at age 5 months, weaning at 12 to 18 months, vitamin D 300 IU/day per os during the first 12 months, calcium 378 mg/day per os from age 5 months to 24 months<BR/>C1: no placebo or other intervention</P>
</TD>
<TD>
<P>I1: 100/183<BR/>C1: 33/46<BR/>
<BR/>based on analysed patients</P>
</TD>
<TD>
<P>not investigated</P>
</TD>
</TR>
<TR>
<TD>
<P>Symbols &amp; abbreviations: I = intervention; C = control</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-10-22 12:41:04 +0200" MODIFIED_BY="Gudrun Paletta" NO="4">
<TITLE MODIFIED="2008-10-22 11:43:14 +0200" MODIFIED_BY="Gudrun Paletta">Secondary outcome data</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-22 12:41:04 +0200" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="4" ROWS="6">
<TR>
<TH>
<P>Characteristic</P>
</TH>
<TH>
<P>Mortality</P>
</TH>
<TH>
<P>Quality of life</P>
</TH>
<TH>
<P>Costs</P>
</TH>
</TR>
<TR>
<TD>
<P>Beser 1994<BR/>
<BR/>I1: vitamin D 400 IU/day per os<BR/>C1: no placebo or other intervention</P>
</TD>
<TD>
<P>not investigated<BR/>
</P>
</TD>
<TD>
<P>not investigated<BR/>
</P>
</TD>
<TD>
<P>not investigated<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<BR/>
<LINK REF="STD-Du-2004" TYPE="STUDY">Du 2004</LINK>
<BR/>
<BR/>I1: fortified milk, averaged calcium 245 mg/day per os<BR/>I2: fortified milk, averaged calcium 245 mg/day per os, vitamin D3 133 IU/day per so<BR/>C1: no placebo or other intervention</P>
</TD>
<TD>
<P>not investigated</P>
</TD>
<TD>
<P>not investigated</P>
</TD>
<TD>
<P>not investigated</P>
</TD>
</TR>
<TR>
<TD>
<P>Duhamel 2000<BR/>
<BR/>I1: vitamin D3 100,000 IU every 3 months per os<BR/>C1: placebo</P>
</TD>
<TD>
<P>not investigated</P>
</TD>
<TD>
<P>not investigated</P>
</TD>
<TD>
<P>not investigated</P>
</TD>
</TR>
<TR>
<TD>
<P>Strand 2002/2003<BR/>
<BR/>I1: promoting of exclusive breastfeeding from birth, supplementation of solid foods at age 5 months, weaning at 12 to 18 months, vitamin D 300 IU/day per os during the first 12 months, calcium 378 mg/day per os from age 5 months to 24 months<BR/>C1: no placebo or other intervention</P>
</TD>
<TD>
<P>not investigated</P>
</TD>
<TD>
<P>not investigated</P>
</TD>
<TD>
<P>not investigated</P>
</TD>
</TR>
<TR>
<TD>
<P>Abbreviations: I = intervention; C = control</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>